Status:
UNKNOWN
New Genomic Techniques and Management of Multidrug-resistant Tuberculosis
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Multi-Drug Resistant Tuberculosis
Eligibility:
All Genders
18+ years
Brief Summary
In the context of the emergence of cases of multidrug-resistant tuberculosis (MDR-TB) it is crucial to improve patient's management. Therefore, assessing the place of innovative strategies enabling th...
Detailed Description
Non-interventional monocentric study on the evaluation of the reliability and validity of a diagnostic test based on a biological collection of M. tuberculosis MDR strains received at the NRC-MyRMA. T...
Eligibility Criteria
Inclusion
- age ≥ 18 years ;
- patient with bacteriologically proven tuberculosis due to a multidrug resistance strain (i.e. resistant to rifampin and isoniazid)
- patient informed of the study and not opposed to participating in the research
Exclusion
- Patient with non MDR tuberculosis ;
- Impossibility of carrying out a phenotypic antibiogram (absence of bacterial culture, contaminated culture)
Key Trial Info
Start Date :
August 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT04397536
Start Date
August 29 2020
End Date
December 1 2022
Last Update
March 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pitié Salpêtrière Hospital
Paris, France, 75013